Potassium channel inhibition innovation creating infrastructure — dalfampridine improving walking speed in multiple sclerosis through potassium channel blockade supporting neurological function, establishing dalfampridine as essential MS mobility infrastructure, with the Dalfampridine Market experiencing expansion driven by MS prevalence growth, mobility emphasis, and neurological drug...